Azita Saleki-Gerhardt - 12 Aug 2025 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role
EVP, CHIEF OPERATIONS OFFICER
Signature
/s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt
Issuer symbol
ABBV
Transactions as of
12 Aug 2025
Net transactions value
-$8,407,055
Form type
4
Filing time
14 Aug 2025, 17:00:06 UTC
Previous filing
25 Apr 2025
Next filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER 1 N. WAUKEGAN ROAD, NORTH CHICAGO /s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt 14 Aug 2025 0001563545

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABBV Common Stock, $0.01 par value Options Exercise $2,324,418 +42,370 +24% $54.86 219,662 12 Aug 2025 Direct
transaction ABBV Common Stock, $0.01 par value Sale $8,407,055 -42,370 -19% $198.42 177,292 12 Aug 2025 Direct F1
holding ABBV Common Stock, $0.01 par value 2,647 12 Aug 2025 Profit sharing trust F2
holding ABBV Common Stock, $0.01 par value 3,873 12 Aug 2025 By spouse F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABBV Option (Right to Buy) Options Exercise $2,324,418 -42,370 -100% $54.86 0 12 Aug 2025 Common Stock 42,370 $54.86 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.34 to $198.58, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Balance in AbbVie Savings program as of August 1, 2025. Balance includes shares acquired pursuant to a dividend reinvestment feature.
F3 The reporting person disclaims beneficial ownership of all securities held by her spouse.
F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 14,124 on February 18, 2017, 14,123 on February 18, 2018, and 14,123 on February 18, 2019.